Saturday 17 October 2026
Export TMO’s income statement to Excel — free account
Thermo Fisher Scientific Inc.
TMO Healthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
690.00
6.49
−0.93%
Follow TMO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
8 | 5 | 4 | 4 |
| 13.14% | 13.02% | 13.52% | 13.51% | ||
| 6.46% | 6.46% | 6.45% | 6.50% | ||
ROIC |
5.92% | 6.12% | 5.56% | 5.80% | |
Return on Tangible Assets |
37.36% | 27.84% | 37.31% | 36.57% | |
Average Days of Receivables |
74.37 | 72.91 | 74.33 | 74.45 | |
Free Cash Flow per Share |
16.26 | 16.81 | 18.25 | 19.84 | |
Free Cash Flow |
6,145.00 | 6,337.00 | 6,789.00 | 7,362.00 | |
Capital Expenditures |
(1,506.00) | (1,481.00) | (1,498.00) | (1,651.00) | |
| Other line items | |||||
Cash ROIC |
7.11% | 6.38% | 7.13% | 7.67% | |
Accounts Receivable Turnover |
5.10 | 5.21 | 5.12 | 5.14 | |
Accounts Payable Turnover |
8.97 | 7.85 | 8.37 | 8.78 | |
Inventory Turnover |
4.60 | 5.06 | 4.99 | 4.90 | |
Average Days of Payables |
44.33 | 50.23 | 45.60 | 43.49 | |
Days of Inventory on Hand |
81.63 | 75.24 | 74.95 | 74.88 | |
Tax Rate |
(0.08) | (0.07) | (0.07) | (0.08) | |
Research and Development Expense of Revenue |
3.23% | 3.14% | 3.08% | 3.03% | |
Selling, General and Administrative Expense of Revenue |
19.62% | 19.60% | 19.55% | 19.48% | |
Share Based Compensation of Revenue |
0.70% | 0.70% | 0.70% | 0.69% | |
Interest Coverage |
5.48 | 5.46 | 5.37 | 5.55 | |
Operating CF/Net income |
1.16 | 1.17 | 1.21 | 1.29 | |
Depreciation/Fixed assets |
0.27 | 0.26 | 0.26 | 0.27 | |
Capex/Depreciation |
(0.54) | (0.53) | (0.53) | (0.56) | |
Revenue per Share |
115.70 | 118.19 | 121.50 | 124.89 | |
Operating CF per Share |
20.24 | 20.74 | 22.28 | 24.29 | |
Capex per Share |
(3.98) | (3.93) | (4.03) | (4.45) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates